Prescription Pricing for the People Act of 2025
Official title: A bill to require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes.
What Do You Think?
How would you vote?
Vote to see the result.
What Happened in Congress?
Not yet voted on the floor.
Where the Bill Stands
- Introduced, done
- Committee, done
- Floor Vote, current stage
- Outcome, not yet
What This Bill Does
This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs.
The report must address whether pharmacy benefit managers (PBMs) (1) reimburse pharmacies owned by the PBM at a higher price than other pharmacies, and (2) implement formulary designs to increase the market share of higher-cost prescription drugs or depress the market share of lower-cost prescription drugs.
The FTC also must provide recommendations to increase transparency in the supply chain, prevent anticompetitive practices, and ensure that consumers benefit from cost savings or efficiencies that result from mergers and consolidations.
Additionally, the FTC must report the number and nature of complaints the FTC receives relating to an allegation of anticompetitive conduct by a manufacturer of a sole-source drug.
Sponsors
Related Documents
Timeline
- SenateCommittee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
- SenateCommittee on the Judiciary. Ordered to be reported without amendment favorably.
- Library of CongressIntroduced in Senate
- SenateRead twice and referred to the Committee on the Judiciary.
- Introduced
- Committee

Comments
Comments with insults, hate speech or personal information are removed.